Prior view was $10.50-$10.70, consensus $10.61. Raises FY25 estimated reported sales view to $93.2B-$93.6B from $91.0B-$91.8B, consensus $91.33B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Genmab reports Q2 worldwide net sales of Darzalex $3.54B
- Trump says drug tariffs probable by August 1, semis coming soon, Bloomberg says
- Johnson & Johnson says Innovative Medicine worldwide operational sales grew 3.8%
- Johnson & Johnson reports Q2 adjusted EPS $2.77, consensus $2.68
- Johnson & Johnson raises FY25 adjusted operational EPS view to $10.63-$10.73